カレントテラピー　30-10　サンプル page 22/42

このページは カレントテラピー　30-10　サンプル の電子ブックに掲載されている22ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
and Swiss Group for Clinical Cancer Research（SAKK）CollaborativeGroup：Cytarabine dose for acute myeloid leukemia.N Engl J Med 364：1027-1036, 20118）Burnett AK, Hills RK, Milligan D, et al：Identifi....

and Swiss Group for Clinical Cancer Research（SAKK）CollaborativeGroup：Cytarabine dose for acute myeloid leukemia.N Engl J Med 364：1027-1036, 20118）Burnett AK, Hills RK, Milligan D, et al：Identification ofpatients with acute myeloblastic leukemia who benefit fromthe addition of gemtuzumab ozogamicin：results of the MRCAML15 trial. J Clin Oncol 29：369-377, 20119）Castaigne S, Pautas C, Terre C, et al；Acute LeukemiaFrench Association：Effect of gemtuzumab ozogamicin onsurvival of adult patients with de -novo acute myeloid leukaemia（ALFA-0701）：a randomised, open -label, phase 3study. Lancet 379：1508 -1516, 201210）Cheson BD, Bennett JM, Kopecky KJ, et al；InternationalWorking Group for Diagnosis, Standardization of ResponseCriteria, Treatment Outcomes, and Reporting Standards forTherapeutic Trials in Acute Myeloid Leukemia：Revisedrecommendations of the International Working Group forDiagnosis, Standardization of Response Criteria, TreatmentOutcomes, and Reporting Standards for Therapeutic Trialsin Acute Myeloid Leukemia. J Clin Oncol 21：4642 -4649,200311）Grimwade D, Walker H, Oliver F, et al：The importance ofdiagnostic cytogenetics on outcome in AML：analysis of 1,612patients entered into the MRC AML 10 trial. The MedicalResearch Council Adult and Children’s Leukaemia WorkingParties. Blood 92：2322-2333, 199812）Dohner H, Estey EH, Amadori S, et al；European LeukemiaNet：Diagnosisand management of acute myeloid leukemiain adults：recommendations from an international expertpanel, on behalf of the European LeukemiaNet. Blood 115：453 -474, 201013）Yanada M, Matsuo K, Emi N, et al：Efficacy of allogeneichematopoietic stem cell transplantation depends on cytogeneticrisk for acute myeloid leukemia in first disease remission：ametaanalysis. Cancer 103：1652-1658, 200514）Cornelissen JJ, van Putten WL, Verdonck LF, et al：Resultsof a HOVON/SAKK donor versus no-donor analysis of myeloablativeHLA-identical sibling stem cell transplantation infirst remission acute myeloid leukemia in young and middleagedadults：benefits for whom? Blood 109：3658-3666, 200715）Koreth J, Schlenk R, Kopecky KJ, et al：Allogeneic stem celltransplantation for acute myeloid leukemia in first completeremission：systematic review and meta -analysis of prospectiveclinical trials. JAMA 301：2349-2361, 200916）Bloomfield CD, Lawrence D, Byrd JC, et al：Frequency ofprolonged remission duration after high -dose cytarabineintensification in acute myeloid leukemia varies by cytogeneticsubtype. Cancer Res 58：4173-4179, 199817）Miyawaki S, Ohtake S, Fujisawa S, et al：A randomized comparisonof 4 courses of standard-dose multiagent chemotherapyversus 3 courses of high -dose cytarabine alone in postremissiontherapy for acute myeloid leukemia in adults：theJALSG AML201 Study. Blood 117：2366-2372, 201118）Kern W, Estey EH：High -dose cytosine arabinoside in thetreatment of acute myeloid leukemia：Review of three randomizedtrials. Cancer 107：116-124, 200619）Mayer RJ, Davis RB, Schiffer CA, et al：Intensive postremissionchemotherapy in adults with acute myeloid leukemia.Cancer and Leukemia Group B. N Engl J Med 331：896 -903,199420）Byrd JC, Dodge RK, Carroll A, et al：Patients with t（8；21）（q22；q22）and acute myeloid leukemia have superior failure-freeand overall survival when repetitive cycles of high -dose cytarabine are administered. J Clin Oncol 17：3767 -3775, 199921）Vellenga E, van Putten W, Ossenkoppele GJ, et al；Dutch-Belgian Hemato -Oncology Cooperative Group（HOVON）；Swiss Group for Clinical Cancer Research CollaborativeGroup（SAKK）：Autologous peripheral blood stem celltransplantation for acute myeloid leukemia. Blood 118：6037-6042, 201122）Duval M, Klein JP, He W, et al：Hematopoietic stem -celltransplantation for acute leukemia in relapse or primaryinduction failure. J Clin Oncol 28：3730-3738, 201023）Breems DA, Van Putten WL, Huijgens PC, et al：Prognosticindex for adult patients with acute myeloid leukemia in firstrelapse. J Clin Oncol 23：1969 -1978, 200524）Karanes C, Kopecky KJ, Head DR, et al：A phaseⅢcomparisonof high dose ARA -C（HIDAC）versus HIDAC plusmitoxantrone in the treatment of first relapsed or refractoryacute myeloid leukemia Southwest Oncology Group Study.Leuk Res 23：787-794, 199925）Ho AD, Lipp T, Ehninger G, et al：Combination of mitoxantroneand etoposide in refractory acute myelogenous leukemia- -an active and well-tolerated regimen. J Clin Oncol 6：213 -217, 198826）Amadori S, Arcese W, Isacchi G, et al：Mitoxantrone, etoposide,and intermediate-dose cytarabine：an effective and tolerableregimen for the treatment of refractory acute myeloidleukemia. J Clin Oncol 9：1210-1214, 199127）Jackson G, Taylor P, Smith GM, et al：A multicentre, open,non -comparative phaseⅡstudy of a combination of fludarabinephosphate, cytarabine and granulocyte colony-stimulatingfactor in relapsed and refractory acute myeloid leukaemiaand de novo refractory anaemia with excess of blasts intransformation. Br J Haematol 112：127-137, 200128）Larson RA, Sievers EL, Stadtmauer EA, et al：Final reportof the efficacy and safety of gemtuzumab ozogamicin（Mylotarg）inpatients with CD33 -positive acute myeloid leukemiain first recurrence. Cancer 104：1442-1452, 200529）Kobayashi Y, Tobinai K, Takeshita A, et al：Phase I/Ⅱstudy of humanized anti -CD33 antibody conjugated withcalicheamicin, gemtuzumab ozogamicin, in relapsed or refractoryacute myeloid leukemia：final results of Japanese multicentercooperative study. Int J Hematol 89：460-469, 200930）Usui N, Takeshita A, Nakaseko C, et al；Japan Adult LeukemiaStudy Group：Phase I trial of gemtuzumab ozogamicinin intensive combination chemotherapy for relapsed orrefractory adult acute myeloid leukemia（AML）：JapanAdult Leukemia Study Group（JALSG）-AML206 study.Cancer Sci 102：1358-1365, 201130Current Therapy 2012 Vol.30 No.101016